Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.77 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.77 |
| ▸ | DUS2 | Q9NX74 | 1/20 | 0.77 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.76 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.76 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.71 |
| ▸ | ABL1 | P00519 | 1/20 | 0.71 |
| ▸ | SRC | P12931 | 1/20 | 0.71 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.71 |
| ▸ | FLT3 | P36888 | 1/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.70 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.70 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.70 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.70 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.70 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.70 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.70 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14671647 | 0.93 | EGFR (0.77) | EGFRERBB3DUS2ERBB2ERBB4 | |
| SCHEMBL30474633 | 0.89 | EGFR (0.81) | EGFRERBB3DUS2ERBB2ERBB4 | |
| SCHEMBL19185507 | 0.89 | EGFR (0.81) | EGFRERBB3DUS2ERBB2ERBB4 | |
| SCHEMBL17538543 | 0.87 | EGFR (0.76) | EGFRERBB3DUS2ERBB2ERBB4 | |
| SCHEMBL29478966 | 0.87 | EGFR (1.00) | EGFRERBB3DUS2ERBB2ERBB4 | |
| SCHEMBL21801932 | 0.87 | EGFR (1.00) | EGFRERBB3DUS2ERBB2ERBB4 | |
| SCHEMBL29617536 | 0.87 | EGFR (1.00) | EGFRERBB3DUS2ERBB2ERBB4 | |
| SCHEMBL14671702 | 0.86 | EGFR (0.82) | EGFRERBB3DUS2ERBB2ERBB4 | |
| SCHEMBL22847994 | 0.85 | EGFR (0.82) | EGFRERBB3DUS2ERBB2ERBB4 | |
| SCHEMBL29615026 | 0.85 | EGFR (0.83) | EGFRERBB3DUS2ERBB2ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371292-B2 | Quinazoline derivative, preparation method therefor, intermediate, composition and application thereof | SHANGHAI PHARMACEUTICALS HOLDINGS CO., LTD. (CN) | 2016-06-21 | — | — | US | claimed |
| US-20140206687-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF | ZHEJIANG UNIVERSITY (CN) | 2014-07-24 | — | — | US | claimed |
| US-9371292-B2 | Quinazoline derivative, preparation method therefor, intermediate, composition and application thereof | SHANGHAI PHARMACEUTICALS HOLDINGS CO., LTD. (CN) | 2016-06-21 | — | — | US | disclosed |
| US-9371292-B2 | Quinazoline derivative, preparation method therefor, intermediate, composition and application thereof | SHANGHAI PHARMACEUTICALS HOLDINGS CO., LTD. (CN) | 2016-06-21 | — | — | US | disclosed |
| US-9371292-B2 | Quinazoline derivative, preparation method therefor, intermediate, composition and application thereof | SHANGHAI PHARMACEUTICALS HOLDINGS CO., LTD. (CN) | 2016-06-21 | — | — | US | disclosed |
| US-20140206687-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF | ZHEJIANG UNIVERSITY (CN) | 2014-07-24 | — | — | US | disclosed |
| US-20140206687-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF | ZHEJIANG UNIVERSITY (CN) | 2014-07-24 | — | — | US | disclosed |
| US-20140206687-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF | ZHEJIANG UNIVERSITY (CN) | 2014-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206687-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF | WEE1, WEE2, CYP4F11 | EGFR 4406/4885ERBB3 4550/4885DUS2 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.